Fibrin Split Products FIB SPLIT

<5 µg/mL
Interpretation:
Under normal conditions, the fibrinolytic process is localized on the fibrin clots because alpha2-antiplasmin and the plasminogen activator inhibitors prevent fibrinolysis from spreading. During disseminated intravascular coagulation (DIC), fibrinolysis spreads and becomes systemic, in which case the degradation of circulating fibrinogen will occur. Fragments that occur are very heterogeneous: products derived from fibrin, soluble completes, degradation products from fibrinogen, and from nonstabilized fibrin. An abnormal fibrinolytic and/or fibrinogenolytic activity shown by high levels of FDP in plasma can also be found in clinical states, such as eclampsia, carcinoma (promyelocytic leukemia), postoperative complications, cardiac and renal disorders, hepatic disorders, fibrinolysis, pulmonary embolism, and deep vein thrombosis (DVT). Positive result indicates the presence of FDP at a concentration ≥2.5 mg/mL. This test should not be used to rule out venous thromboembolism.